AI biotechs vs IBB

The chart shows the growth of an initial investment of $10,000 in AI biotechs vs IBB, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Oct 4, 2021, AI biotechs vs IBB's average daily return is -0.04%, while the average monthly return is -1.20%.

Historically, 42% of months were positive and 58% were negative. The best month was Jul 2023 with a return of +33.3%, while the worst month was Aug 2023 at -28.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, AI biotechs vs IBB closed higher 47% of trading days. The best single day was Jul 12, 2023 with a return of +19.7%, while the worst single day was Feb 13, 2024 at -10.3%.

AI biotechs vs IBB has an annualized alpha of -24.75%, beta of 1.49, and R² of 0.28 versus S&P 500 Index. Calculated based on daily prices since October 04, 2021.

• This portfolio participated in 169.27% of S&P 500 Index downside but only 48.96% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.28 means this portfolio moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AI biotechs vs IBB has an expense ratio of 0.09%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

AI biotechs vs IBB ranks 4 for risk / return — in the bottom 4% of portfolios on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

AI biotechs vs IBB Sharpe ratios as of Apr 10, 2026 (values are recalculated daily):

• 1-Year: 0.15
• All Time: -0.42

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 1.87 to 2.87, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests weaker risk-adjusted returns than most portfolios, possibly due to lower returns, higher volatility, or both. It may be worth reviewing the allocation. You can use the Portfolio Optimization tool to explore options for improving the Sharpe ratio.

The chart below shows the rolling Sharpe ratio of AI biotechs vs IBB compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

AI biotechs vs IBB provided a 0.05% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the AI biotechs vs IBB. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AI biotechs vs IBB was 69.31%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current AI biotechs vs IBB drawdown is 64.94%.

The chart below shows the rolling one-month volatility.